Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tizaterkib - Antengene Corporation

Next Previous
Drug Profile

Tizaterkib - Antengene Corporation

Alternative Names: ATG-017; AZD-0364

Latest Information Update: 16 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Antengene Corporation; AstraZeneca
  • Class Antineoplastics; Fluorobenzenes; Imidazoles; Pyrazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours
  • No development reported Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 31 May 2024 Adverse events, efficacy and pharmacokinetics data from a phase-I trial in Solid tumours presented at the presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 24 May 2024 Antengene Therapeutics terminates a phase I ERASER trial in Haematological malignancies (Combination therapy, Late-stage disease) and Solid tumours (Combination therapy, Late-stage disease) in USA, Australia (PO) due to an internal decision to re-prioritise the company's entire pipeline and phase I portfolio (NCT04305249)
  • 24 May 2024 Antengene Therapeutics terminates a phase I ERASER trial in Haematological malignancies (Monotherapy, Late-stage disease) and Solid tumours (Monotherapy, Late-stage disease) in USA, Australia (PO) due to an internal decision to re-prioritise the company's entire pipeline and phase I portfolio (NCT04305249)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top